Citations

Mayo Clinic

Clear

2817 citation(s) found for "C, Liu".

Book-Shaped Acellular Fibrocartilage Scaffold with Cell-loading Capability and Chondrogenic Inducibility for Tissue-Engineered Fibrocartilage and Bone–Tendon Healing
Chen, Can , Liu, Fei , Tang, Yifu , Zheng, Cheng , Chen, Yang , Li, Muzhi , Zhao, Chunfeng , Sun, Lun‐Quan , Lü, Hongbin , Zheng, Cheng , Chen, Yang , Li, Muzhi , Lu, Hongbin , Qu, Jin , Cao, Yong Bing , Hu, Jianzhong

ACS Applied Materials & Interfaces | January 9, 2019 | Volume: 11 | Issue: 3 | Pages: 2891-2907

10.1021/acsami.8b20563 | PMID 30620556 Get It

Effect of Biomaterial Electrical Charge on Bone Morphogenetic Protein-2-Induced In Vivo Bone Formation
Olthof, Maurits G.L. , Liu, Xifeng , Dadsetan, Mahrokh, Tryfonidou, Marianna A. , Yaszemski, Michael J. , Lu, Lichun , Kempen, Diederik H.R. , Dhert, Wouter J.A.

Tissue Engineering Part A | January 5, 2019 | Volume: 25 | Issue: 13-14 | Pages: 1037-1052

10.1089/ten.tea.2018.0140 | PMID 30612538 Get It

Biomaterials that act as both protein delivery vehicle and scaffold can improve the safety and efficacy of bone morphogenetic protein-2 (BMP-2) for clinical applications. However, the optimal scaffold characteristics are not known. The osteoinductive and osteoconductive capacity of a fixed electrically charged surface is thus far unexplored. Therefore, in this study, we aim to investigate the effect of different electrical states on BMP-2-induced bone formation in oligo[(polyethylene glycol) fumarate] (OPF) hydrogels. Neutral, negatively, or positively charged scaffolds were fabricated using unmodified OPF (neutral charge), sodium methacrylate crosslinked OPF (negative charge), or [2-(methacryloyloxy) ethyl] trimethylammonium chloride crosslinked OPF (positive charge), respectively. To allow investigation of surface charge for different BMP-2 release rates, three BMP-2 release profiles were generated by protein encapsulation into poly(lactic-co-glycolic acid) microspheres and/or adsorption on the OPF composite. Release of radiolabeled 125 I-BMP-2 was analyzed in vitro and in vivo and bone formation was assessed after 9 weeks of subcutaneous implantation in rats. Negatively charged OPF generated significantly more bone formation compared with neutral and positively charged OPF. This effect was seen for all three loading methods and subsequent BMP-2 release profiles. Along with charge modifications, a more sustained release of BMP-2 improved overall bone formation in OPF composites. Overall, this study clearly shows that negative charge enhances bone formation compared with neutral and positive charge in OPF composites. Impact Statement Biomaterials can play a dual role in bone regeneration: they enable local sustained delivery of growth factors, such as bone morphogenetic protein-2 (BMP-2), while they provide structural support as scaffold. By better imitating the properties of native bone tissue, scaffolds may be both osteoconductive and osteoinductive. The latter can be achieved by modifying the electrical charge of the surface. The present work uses tunable oligo[(polyethylene glycol) fumarate] hydrogel and demonstrates that negative charge enhances BMP-2-induced bone formation compared with neutral or positive charge. Altogether, this indicates that tissue-specific surface charge modifications of biomaterials hold great promise in the field of tissue regeneration.
Scrambler therapy for treatment of chemotherapy-induced peripheral neuropathy.
Weisbrod, Breanna L., Pachman, Deirdre R. , Seisler, Drew K., Barton, Debra L. , Fee-Schroeder, Kelliann C., Liu, Heshan , Loprinzi, Charles L. , Smith, Thomas J. , Lachance, Daniel Honore , Cheville, Andrea

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 9622-9622

10.1200/jco.2014.32.15_suppl.9622 Get It

The effect of SETD2 mutation (mts) on histone 3 lysine 36 tri-methylation (H3K36me3) and correlation with clinical outcome in patients (pts) with metastatic clear cell renal cell carcinoma (ccRCC) enrolled in COMPARZ.
D’Amelio, Anthony M., Hsieh, James J. , Souza, Paul L. de , Deen, Keith C., Langmuir, Peter, Liu, Yuan , Ho, Thai H. , Choueiri, Toni K. , Motzer, Robert J.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4583-4583

10.1200/jco.2014.32.15_suppl.4583 Get It

TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).
Gelman, Rebecca , Krop, Ian E. , Melisko, Michelle , Agar, Nathalie Y.R. , Blackwell, Kimberly , Connolly, Roisín M. , Poznak, Catherine Van , Puhalla, Shannon, Ryabin, Nicole, Lawler, Elizabeth S, Ibrahim, Nuhad K. , Liu, Minetta C. , Agar, Nathalie Y R , Freedman, Rachel A. , Wefel, Jeffrey S. , Lowe, Alarice Cheng-Yi , Niravath, Polly Ann , Wolff, Antonio C. , Winer, Eric P. , Lin, Nancy U.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 528-528

10.1200/jco.2014.32.15_suppl.528 Get It

Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.
Sweeney, Christopher, Liu, Glenn , Jarrard, David Frasier, Eisenberger, Mario A. , Wong, Yu‐Ning, Hahn, Noah M. , Cooney, Matthew M. , Shevrin, Daniel H. , García, Jorge A. , DiPaola, Robert S. , Chen, Yu‐Hui , Carducci, Michael A. , Kohli, Manish , Vogelzang, Nicholas J. , Dreicer, Robert , Picus, Joel , Hussain, Maha

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: LBA2-LBA2

10.1200/jco.2014.32.15_suppl.lba2 Get It

Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Chapman, Judy‐Anne W., Burnell, Margot J., Levine, Mark N. , Whelan, Timothy J. , Albain, Kathy S. , Perez, Edith A. , Virk, Shakeel , O’Brien, Patti, Shepherd, Lois E. , Gelmon, Karen A. , Liu, Shuzhen , Pritchard, Kathleen I. , Rugo, Hope S. , Nielsen, Torsten O.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 11019-11019

10.1200/jco.2014.32.15_suppl.11019 Get It

Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).
Tan, Antoinette R. , Wong, Serena, Warren, Robert, Eng‐Wong, Jennifer , Liu, Minetta C. , Zelnak, Amelia, Shih, Weichung, Ganesan, Shridar , Grana, Generosa , Toppmeyer, Deborah , Lin, Yong , Isaacs, Claudine

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 531-531

10.1200/jco.2014.32.15_suppl.531 Get It

Dosimetric analysis of distal esophageal adenocarcinoma patients treated by intensity-modulated proton therapy with small spot size.
Liu, Chenbin , Bhangoo, R.S. , Rule, William G., Ross, Helen J. , Paripati, Harshita, Jaroszewski, Dawn E. , Beamer, Staci E. , Fleischer, David E., Ramirez, Francisco C. , Ding, Xiaoning, Ashman, Jonathan B. , Sio, Terence T. , Bues, Martin , Liu, Wei

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 159-159

10.1200/jco.2018.36.4_suppl.159 Get It

159 Background: Intensity-modulated proton therapy (IMPT) with small spot size has the potential to reduce dose to normal tissues but also introduces new confounding factors such as setup uncertainty, range uncertainty, and interplay effects due to breathing motion. We investigated plan quality and robustness of IMPT with small spot size for distal esophageal adenocarcinoma (DEA). Methods: 19 patients with DEA treated by IMPT were retrospectively evaluated. Spot sizes ranged from 2 to 6mm, with spot spacing of 5mm. All plans were generated using a commercial treatment planning system. In-house-developed dose-evaluation software modeled time-dependent spot delivery to incorporate interplay effects. Dose-volume-histogram (DVH) indices were used to evaluate plan quality and robustness was evaluated using the DVH band method. Results: For plan quality, median values of clinical target volume D95% and D5%-D95% (normalized to the prescribed doses), total lung mean dose, heart mean dose, and cord Dmax were 1.014, 0.035, 3.82Gy[RBE], 7.73Gy[RBE], 39.16Gy[RBE], respectively. For plan robustness, median band widths of the aforementioned DVH indices were 0.018, 0.048, 0.60Gy[RBE], 4.17Gy[RBE], and 2.36Gy[RBE], respectively. For interplay effects, median values of the aforementioned DVH indices were 0.99, 0.061, 4.07Gy[RBE], 7.87Gy[RBE], and 39.66Gy[RBE], respectively. Seven patients underwent esophagectomy after neoadjuvant chemoradiation, and five, three, and one of them achieved downstaging, near complete response, and pathologic complete response, respectively; R0 resection was achieved in all cases. For all patients, acute side effects were mostly limited to grades 1-2 only. The only grade 3 adverse events were related to feeding tube placement (8 patients); there were no RT-induced pneumonitis or other lung-related toxicities. Conclusions: IMPT plans with small spot size for DEA have good target dose coverage, homogeneity and normal tissue protection. Treatment plans are also robust to uncertainties and interplay effects. Early clinical results demonstrate low acute toxicity and encouraging clinical and pathologic response.
Rapid conjugation of nanoparticles, proteins and siRNAs to microbubbles by strain-promoted click chemistry for ultrasound imaging and drug delivery
Liu, Xifeng , Xie, Feng , Chen, Shigao , Lu, Lichun , Gong, Ping , Miller, A. Lee , Gong, Ping , Song, Pengfei , Miller, Alan Lee

Polymer Chemistry | December 26, 2018 | Volume: 10 | Issue: 6 | Pages: 705-717

10.1039/c8py01721b | PMID 36187167 Get It

Strain-promoted alkyne–azide cycloaddition (SPAAC) click chemistry was applied for the rapid conjugation of nanoparticles, proteins, and siRNA-micelles to ultrasound microbubbles.